Multiple myeloma can occur in individuals with no detectable underlying medical condition. The most likely underlying cause is chronic inflammation of the bone marrow, from infection by a virus, bacteria, or fungal spore. Diagnosis can be made through careful medical history and physical examination, X-rays, and, less commonly, biopsy. The American Cancer Society states that multiple myeloma usually develops in individuals who have had other medical conditions, are old, immunocompromised, or have a family member with the disease. There is no known cure, although treatment of the disease depends on the type and severity of the disease. Prognosis is poor.
A national estimate of the number of persons with a diagnosis of myeloma in the general population and those diagnosed with multiple myeloma is presented for the first time in this report. The overall number of Americans who develop multiple myeloma exceeds the number of Asians, Hispanics, and whites with multiple myeloma annually in the United States.
For a minority with MM, recent advances in treatment options and the identification, early detection and treatment with high-level remission rates have greatly improved survival rates. New therapies are often less toxic and less intense than older drug regimens, thus enabling them to be used in a curative fashion.
Patients with MM experience a wide range of symptoms and have a relatively short survival rate even in optimal clinical settings. MM is a deadly disease that affects many organs and systems including the skeleton, skin, CNS and kidneys. MM is a disease that has both curative and palliative goals. In most patients with MM, treatment results in significant time and expense savings and improvements in quality of life in terms of pain control and disease control.
Immunosuppressive or glucocorticoid-sparing regimens may be used, but bone marrow stem cell [transplant](https://www.withpower.com/clinical-trials/transplant)ation has not been used. Anti-CD20 merscriptor therapy such as rituximab may be used in patients who have failed all other therapeutic approaches. There was little evidence of use of radiation therapy, radiation therapy, or other therapies.
After a follow-up of nearly 5 years, Krdd is followed by increased post-KDR auto-hct titer levels, but this can, in general, be managed with standard immunosuppression and dose reduction.
These data suggest that a substantial proportion of multiple myeloma runs in families supporting the hypothesis that genetic predisposition plays a role in multiple myeloma disease susceptibility.
The prevalence is significantly higher in men (14%), but the average age of onset is higher in women (64) than men (63), because women live longer (82). Most individuals have at least one of the major risk factors associated with the disease: smoking, alcohol, and dietary factors. The average age that multiple myeloma is diagnosed is older (67) in women than men (57), because it is harder to recognize the disease in women.
This is the first clinical trial of krdd followed by auto-hct treatment that is reported in the literature. The treatment was well tolerated, and the tumor-specific and immune-competence markers were significantly improved as compared with those observed in the first krdd study.
It seems that there is a small percentage of the population with the myeloma that has myeloma cell spread to other parts within the body (in particular spleen and lymph nodes) within 1 year of diagnosis.
Multiple myeloma treatment is largely based on how much light patients respond to chemotherapy. Scientists still lack effective treatment algorithms. [Targeted therapies and bisphosphonates are more effective treatment in terms of survival, disease-free and event-free survival; they can be applied to patients with multiple myeloma with good response to chemotherapy and with excellent quality of life. These treatments can be used in patients who do not obtain satisfactory response to chemotherapy and who are candidates of stem cell transplant or allogeneic stem cell transplantation (G-MECOM, NOD-X2).] [http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0873.2003.